Elevated hemoglobin A1c is associated with the presence of pancreatic cysts in a high-risk pancreatic surveillance program

Ariel Bar-Mashiah*, Anne Aronson, Monica Naparst, Christopher J. DiMaio and Aimee L. Lucas

Abstract

Background: Emerging evidence demonstrates that surveillance of individuals at high-risk (HRIs) of developing pancreatic adenocarcinoma allows for identification and treatment of resectable tumors with improved survival. Population-based data suggest that hyperglycemia may be present up to three years before the development of pancreatic cancer. We investigated whether elevated hemoglobin A1c (HbA1c) is associated with the development of pancreatic cysts in a pancreatic surveillance program.

Methods: We performed a retrospective study of HRIs who underwent pancreatic surveillance at a single institution between May 2013 and March 2019, according to published criteria. We collected demographic information, clinical data including HbA1c, and imaging results. We compared data using univariable and multivariable analyses. Our primary outcome was the presence of pancreatic cysts on initial surveillance in patients with elevated HbA1c.

Results: Ninety-eight patients underwent surveillance imaging via EUS or MRCP and seventy-four patients met inclusion criteria. Thirty patients were found to have cysts on initial imaging. Older age (p < 0.01) and HbA1c in the prediabetic range or higher (p = 0.01) were associated with the presence of cysts or solid lesions on univariable analysis. After controlling for confounders, age (aOR 9.08, 95% CI 3.09 - 36.10), and HbA1c > 5.7% (aOR 5.82, 95% CI 1.50 - 22.54) remained associated with presence of cysts and solid lesions in HRIs. In patients with cysts or solid lesions there was a strong association between increased age and elevated HbA1c (p < 0.01).

Conclusion: HRIs with elevated HbA1c were more likely to have pancreatic cysts compared to individuals with lower HbA1c on initial imaging in a pancreatic surveillance program. These findings may help tailor the surveillance protocols for those at increased risk of developing pancreatic adenocarcinoma.

Keywords: Type 3c diabetes, Pancreatic diabetes, Early detection, Pancreatic cysts
The majority of these lesions remain stable during surveillance; however, features such as the presence of multifocal cysts, cyst growth, and the presence of a deleterious germline mutation have been associated with neoplastic progression to high-grade dysplasia or pancreatic cancer [11, 13].

New-onset diabetes mellitus has been established as a prelude to pancreatic adenocarcinoma [14]. Approximately 85% of patients at pancreatic cancer diagnosis have impaired fasting blood glucose or diabetes mellitus, suggesting this may be a near universal marker for progression to pancreatic adenocarcinoma and can aid in its diagnosis during the disease’s earlier stages [15]. Furthermore, elevations in fasting blood glucose may be seen up to 36 months prior to pancreatic adenocarcinoma diagnosis [16].

The aim of our study is to identify whether there is an association between elevated Hemoglobin A1c (HbA1c) and the presence of pancreatic cysts in a high-risk pancreatic surveillance program.

Methods
Cohort recruitment
From May 2013 to March 2019 subjects were enrolled in a high-risk registry at a tertiary academic medical center with a comprehensive multidisciplinary pancreas program. The registry and this study are institutional review board approved, and all subjects provided informed written consent. HRIs were included if they met International Cancer of the Pancreas Screening (CAPS) criteria or American College of Gastroenterology (ACG) clinical guidelines for hereditary gastrointestinal cancer (Table 1) [4, 17, 18]. HRIs were referred to the registry via physicians, genetic counselors, and/or self-referral. After providing informed consent, all patients completed a survey that included questions relating to personal medical history, family history, known genetic mutations, social history and environmental exposures such as tobacco and alcohol use history.

Surveillance protocol
HRIs were offered initial surveillance via endoscopic ultrasound (EUS) and/or magnetic resonance imaging with cholangiopancreatography (MRCP) at least annually, in accordance with existing guidelines [4, 17, 18]. Patients who met criteria for pancreatic cancer surveillance (Table 1), had abdominal imaging with either EUS or MRCP, and HbA1c levels in medical record within one year of office visit were included in this analysis. If patients had multiple HbA1c levels within one year of an office visit, we used the value collected closest to the office visit date.

MRCP was conducted using a GE Signa HDxt 1.5T machine. EUS was conducted and interpreted by one experienced therapeutic endoscopist using an Olympus GF-UCT180 Curvilinear Array Ultrasound Echoendoscope. Five patients had their imaging conducted at an outside institution; however, all relevant medical records were available for review. Imaging data were extracted directly from the electronic medical record. Only findings from initial surveillance imaging were included in our analysis (Fig. 1).

Statistical analyses
Statistical analyses were conducted using SPSS version 22.0 software (SPSS, Inc., Chicago, IL) with two-sided significance set at a \( p \)-value of .05. Categorical variables were summarized using descriptive statistics, with comparisons between groups performed using Pearson chi-square test for univariate analysis. Odds ratios and 95% confidence intervals were calculated using logistic regression adjusting for covariates. Cochran-Armitage trend test was conducted using XLSTAT (Microsoft Excel version 16.25) with two-tailed \( p \)-value set at .05.

Covariates
Older age was considered \( \geq 60 \) years. Patients were considered overweight or obese if body mass index (BMI) \( \geq 25.0 \) in accordance with Centers for Disease Control and Prevention guidelines. Tobacco use was considered in former and current smokers compared to never smokers. Elevated HbA1c was > 5.7%, which is the clinical criteria for prediabetes.

Results
Ninety-eight patients underwent pancreatic surveillance by EUS or MRCP. Seventy-four subjects met inclusion

| Criteria | Age at Inclusion |
|----------|------------------|
| FDR of affected family member in FPC kindred | \( \geq 50 \) years or 10 years younger than youngest affected family member |
| STK11 mutation (Peutz-Jeghers syndrome) | \( \geq 40 \) years |
| BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6 mutation with affected FDR or SDR | \( \geq 50 \) years or 10 years younger than youngest affected family member |
| CDKN2A | \( \geq 40 \) years |
| PRSS1 mutation (hereditary pancreatitis) | \( \geq 40 \) years |

FDR first-degree relative, FPC Familial Pancreatic Cancer, defined as kindreds with 2 affected FDRs, SDR second-degree relative
criteria: 45 (60.8%) were female, 62 (83.8%) identified as white/Caucasian, 6 (8.1%) as Black, and 4 (5.4%) as Hispanic/Latino (Table 2). Eight patients (10.8%) were found to have a pathogenic/likely pathogenic (P/LP) variant in BRCA1, while 13 (17.6%) carried a P/LP variant in BRCA2. One patient had a P/LP variant in ATM (1.4%) and 2 patients (2.7%) had Lynch Syndrome. All patients with a germline P/LP variant had at least one first-degree or second-degree relative with pancreatic adenocarcinoma. Fifty (67.5%) patients had familial pancreatic cancer (FPC), defined as individuals with 2 or more blood relatives with pancreas cancer, at least 1 of whom was a first-degree relative of the patient, in the absence of a known P/LP germline variant that has been associated with pancreatic adenocarcinoma. Forty-seven (63.5%) patients were older than 60 years. Nineteen patients (25.7%) had HbA1c values greater than 5.7%. Thirty-three (44.6%) subjects identified as former or current smokers. Twenty-seven (36.5%) patients were in the healthy BMI range (< 25.0), 37 (50.0%) were overweight (25.0 – 29.9) and 10 (13.5%) patients were obese (≥ 30).

The mean follow-up time in clinic was 2.6 years (range 0.2 – 6.1 years). Thirty patients were found to have pancreatic cysts on initial imaging. The clinical impression by the treating physicians at our institution (ALL, CJD) is that the majority of the cysts were consistent with sub-centimeter branch duct intraductal papillary mucinous neoplasms (IPMNs), although we do not have tissue confirmation of cyst subtypes for most patients. A few cysts did exhibit worrisome features: 2 patients had main
Table 2 Characteristics of the study cohort

| Variables                                      | n (%)      |
|------------------------------------------------|------------|
| Total                                          | 74 (100.0) |
| Age                                            |            |
| ≤ 40                                           | 2 (2.7)    |
| 41–50                                          | 2 (2.7)    |
| 51–60                                          | 23 (31.1)  |
| 61–70                                          | 28 (37.8)  |
| 71–80                                          | 17 (23.0)  |
| > 80                                           | 2 (2.7)    |
| Sex                                            |            |
| Male                                           | 29 (39.2)  |
| Female                                         | 45 (60.8)  |
| Race                                           |            |
| Asian                                          | 1 (1.4)    |
| Pacific Islander                               | 1 (1.4)    |
| Black/African American                         | 6 (8.1)    |
| White/Caucasian                                | 62 (83.8)  |
| Unknown/Other/Prefer Not to Answer             | 4 (5.3)    |
| Ethnicity                                      |            |
| Hispanic/Latino                                | 4 (5.4)    |
| Not Hispanic/Latino                            | 70 (94.6)  |
| Body Mass Index                                |            |
| Healthy (< 25.0)                               | 27 (36.5)  |
| Overweight (25.0–29.9)                         | 37 (50.0)  |
| Obese (≥ 30.0)                                 | 10 (13.5)  |
| Tobacco Use                                    |            |
| Current Smokers                                | 3 (4.1)    |
| Former Smokers                                 | 30 (40.5)  |
| Never Smokers                                  | 41 (55.4)  |
| Surveillance Categories                        |            |
| Familial Pancreas Cancer                       | 50 (67.5)  |
| BRC1 w/ FH                                     | 8 (10.8)   |
| BRC2 w/ FH                                     | 13 (17.6)  |
| Lynch Syndrome w/ FH                           | 2 (2.7)    |
| ATM w/ FH                                      | 1 (1.4)    |
| Hemoglobin A1c                                  |            |
| > 5.7%                                         | 19 (25.7)  |
| ≤ 5.7%                                         | 55 (74.3)  |
| Mean Follow Up Time in Years (SD)              | 2.6 (SD 1.7)|

FH family history, SD standard deviation

pancreatic duct diameter between 5 and 9 mm, 2 cysts grew > 5 mm within a two-year period, 1 cyst had a 3 mm nodule, and 2 cysts were ≥ 3 cm [19]. One subject had both a cyst > 3 cm which exhibited growth of > 5 mm or greater in a two-year period; this patient remains in surveillance. One patient had both a cyst > 3 cm with a 4 mm nodule; upon resection this demonstrated IPMN with high grade dysplasia. A total of five patients had worrisome features; of those patients, three (60%) exhibited HbA1c > 5.7%. Other features noted were 22 patients with multifocal cysts, 22 patients with sub-centimeter cysts, and 2 patients with solid lesions found on initial imaging (Table 3). One patient with a solid lesion had an elevated HbA1c and was found to have pancreatic cancer. The other patient remains in surveillance, and the solid lesion was not redemonstrated on subsequent imaging.

Older age ($p < 0.01$) and HbA1c in the prediabetic range or higher ($p = 0.01$) were associated with the presence of pancreatic abnormalities on univariable analysis (Table 4). After controlling for confounders, age ≥ 60 (aOR 8.36, 95% CI 2.09–33.44), and HbA1c > 5.7% (aOR 5.48, 95% CI 1.41–21.23) remained associated with presence of cysts in HRIs. In further analyses, age ≥ 60 (aOR 9.08, 95% CI 2.29–36.10), and HbA1c > 5.7% (aOR 5.82, 95% CI 1.50–22.54) remained associated with presence of cysts or solid lesions in HRIs (Table 5).

Patients with cysts or solid lesions were categorized into cohorts according to HbA1c status (> 5.7% v ≤ 5.7%). Cochran-Armitage trend test in patients with cysts or solid lesions showed a significant association between elevated HbA1c and increased age ($p < 0.01$) (Fig. 2).

Discussion

The results of this study demonstrated an association between elevated HbA1c, age and the presence of pancreatic cysts on initial surveillance imaging in HRIs. The presence of IPMNs and pancreatic intraepithelial neoplasia (PanINs) indicates a risk of ductal cancer not only in the lesion itself but within the entire pancreas [20]. A majority of patients with cysts in our study had sub-centimeter branch duct IPMNs, which is consistent

Table 3 Pancreatic Abnormalities Found in HRIs on Initial Imaging

| Abnormality Detected | N (%)      |
|----------------------|------------|
| IPMNs*              | 30 (40.5)  |
| Sub-centimeter cysts | 22 (29.7)  |
| Multifocal cysts     | 22 (29.7)  |
| Worrisome Features$^b$ | 5 (6.8)  |
| Cysts > 3 cm         | 2 (2.7)    |
| Cyst with solid component | 1 (1.4) |
| MPD 5–9 mm           | 2 (2.7)    |
| Solid lesions        | 2 (2.7)    |

*IPMN intraductal papillary mucinous neoplasm, MPD main pancreatic duct
$^b$Worrisome features are based on the 2017 Revised Fukuoka Consensus Guidelines [19]
with prior reports in HRIs [12]. Pancreatic cancer surveillance programs have shown that up to 34% of HRIs ages 50–59 have pancreatic lesions, and this proportion increased to 54% in those ages 60–69 [12]. The majority of these lesions are small (< 1 cm) branch duct IPMNs or PanINs, and are more commonly detected in HRIs than in the general population. Our study supports these data, demonstrating that pancreatic cysts are more commonly identified in older HRIs.

Prior studies have reported an association between older age and increased HbA1c levels in nondiabetic populations (HbA1c < 5.7%) [21]. While our analyses do not argue against an association between increasing HbA1c and age, we focused on individuals at increased risk of pancreatic cancer. We have additionally sought to focus on whether impaired glucose metabolism, evidenced here by HbA1c levels above the prediabetic cutoff, are associated with the presence of pancreatic cysts in a unique cohort of individuals at high-risk of developing pancreatic cancer.

In HRIs, neoplastic progression has been described to occur more commonly in germline mutation carriers and individuals with multifocal cysts [11]. In our study, 22 (29.7%) patients had multifocal cysts and 24 (32.4%) carried P/LP germline variants associated with pancreatic cancer. Mean surveillance in this study was 2.6 years. Therefore, our analyses focused on initial surveillance imaging studies; with a longer surveillance period, we will be able to determine if these factors and HbA1c levels predict neoplastic progression.

Tobacco is a known independent risk factor for pancreatic cancer [22]. A recent study of HRIs has described an association between increased age and smoking history with the development of pre-malignant lesions or early pancreatic adenocarcinoma [23]. Similar to their study, we found that increased age is associated with the development of cysts; however, we did not find that smoking was associated with precursor lesions such as IPMNs and PanINs. However, it is possible that among patients that smoke, pack-year tobacco exposure differed between the European and US-based studies. Further studies on the impact of tobacco exposure in HRIs are needed.

Two major causes of diabetes are pancreatic beta cell dysfunction and peripheral insulin resistance. However, type 3c diabetes is another form of diabetes caused by a variety of pancreatic diseases with varying mechanisms of hyperglycemia [24]. Up to 80% of individuals with pancreatic cancer have evidence of impaired glycemic metabolism, and a diagnosis of new-onset diabetes has been associated with up to an 8-fold increased risk of pancreatic cancer [15, 25]. Elevations in fasting blood glucose may be apparent up to 36 months prior to a diagnosis of pancreatic cancer [16]. Recent reports suggested that FPC kindreds have a similar abnormalities in their glycemic profile prior to the diagnosis of pancreatic cancer compared to those with sporadic pancreatic cancer [26]. In this study, one patient with multifocal cysts went on to progress to adenocarcinoma associated with hyperglycemia. Our study provides additional support for further evaluation of glycemic profiles in HRIs to improve risk stratification [16].

Models to distinguish between pancreatic cancer-induced hyperglycemia and the prediabetes of type 2 diabetes mellitus have found that variables typically associated with increased risk of type 2 diabetes, including elevated BMI, hypercholesterolemia and hypertriglyceridemia, were associated with lower pancreatic adenocarcinoma risk [27]. Others have noted that new-onset diabetes prior to pancreatic cancer development is associated with paradoxical weight loss [28].

### Table 4

| Independent Variable          | Patients with Cysts or Solid Lesions (n = 32; 43.2%) | Patients Without Cysts or Solid Lesions (n = 42; 56.8%) | P value |
|-----------------------------|------------------------------------------------------|--------------------------------------------------------|---------|
| Age ≥ 60                    | 28 (87.5)                                             | 21 (50.0)                                              | <.01    |
| Female Sex                   | 21 (65.6)                                             | 24 (57.1)                                              | .46     |
| HbA1c > 5.7%                 | 13 (40.6)                                             | 6 (14.3)                                               | .01     |
| BMI ≥ 25                     | 21 (65.6)                                             | 26 (61.9)                                              | .74     |
| Current and Former Smokers   | 17 (53.1)                                             | 16 (38.1)                                              | .20     |
| FPC                          | 23 (71.9)                                             | 28 (66.6)                                              | .45     |

*HbA1c* Hemoglobin A1c, *BMI* Body Mass Index, *FPC* Familial pancreatic cancer

### Table 5

| Independent Variable          | P value | aOR  | 95% CI for aOR |
|-----------------------------|---------|------|----------------|
|                            |         |      | for aOR        |
|                            |         |      | Lower Upper    |
| Age ≥ 60                    | < .01   | 9.08 | 2.29 36.10     |
| HbA1c > 5.7%                 |         | 5.82 | 1.50 22.54     |
| Current and Former Smokers   | .38     | 1.65 | .54 5.05       |
| BMI ≥ 25                     | .45     | .63  | .19 2.10       |
| Female Sex                   | .07     | 3.17 | .90 11.05      |
| FPC                          | .80     | 1.17 | .35 3.97       |

*HbA1c* Hemoglobin A1c, *BMI* Body Mass Index, *FPC* Familial pancreatic cancer
analyses have also demonstrated that obesity is associated with the development of pancreatic cancer [29–31]. In our study, we were not able to draw conclusions between BMI and cyst development in HRIs since the majority (86%) of our patients were found to be healthy or overweight. Future studies should address longitudinal changes in BMI and glycemic profiles in HRIs.

Other studies have evaluated the association between treatment for diabetes and overall survival in patients with pancreatic adenocarcinoma [32]. For example, one study found that metformin, a biguanide oral hypoglycemic commonly used as first-line therapy in patients with diabetes, is associated with increased survival in patients with pancreatic cancer [33]. Since only four of our subjects were found to be in the diabetic range (HbA1c ≥ 6.5%), we were unable to evaluate the impact of diabetes treatment in HRIs.

There are a number of strengths and limitations to this study. Although we assessed the presence of pancreatic cysts in HRIs, the presence of cysts does not suggest that these lesions will eventually progress into cancer. Additionally, as this study was retrospective in nature, we were not able to collect HbA1c and BMI values at the exact date of surveillance imaging. Patients were only included if they had HbA1c testing within one year of a clinical visit. However, one strength of this approach is that HbA1c data did not alter clinical decisions and prompt earlier investigations. We were not able to conduct a subgroup analysis in patients with worrisome features due to the small number of patients that fell into this category. Additionally, we do not have any information regarding differentiation of IPMN subtypes except for one patient who had a surgical resection. Since this study was conducted only in patients with a high risk of developing pancreatic cancer, the results are not generalizable to the general population.

At this time, HRIs with cysts in the setting of elevated HbA1c should continue surveillance under published guidelines [4, 18]. In newly established guidelines, there was expert consensus around the need for glucose testing (fasting glucose or HbA1c) to detect new-onset diabetes in HRIs. Additionally, there was consensus that the new emergence of diabetes in HRIs should prompt additional investigation [4]. Further prospective surveillance data are required to evaluate risk factors for neoplastic progression in HRIs with cysts and elevated HbA1c.

Conclusion

In conclusion, our study demonstrates that elevated HbA1c is associated with the presence of pancreatic cysts on initial surveillance imaging in HRIs in a high-risk pancreatic surveillance program. Identification of pancreatic abnormalities and other risk factors that predict neoplastic progression to adenocarcinoma or high-grade precursor neoplasms may improve surveillance programs and guide management of detected lesions in the future. Future studies evaluating longitudinal changes in the glycemic and metabolic profiles in HRIs should be pursued.

Abbreviations

HRIs: High-risk individuals; Hemoglobin A1c: HbA1c; EUS: Endoscopic ultrasound; MRCP: Magnetic resonance cholangiopancreatography; BMI: Body mass index; FPC: Familial pancreatic cancer; IPMN: Intraductal papillary mucinous neoplasm; PanIN: Pancreatic intraepithelial neoplasia; FH: Family history

Acknowledgments

Not applicable.
Authors’ contributions
AB: Acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision for important intellectual content, statistical analysis, obtained funding AA: Acquisition of data, critical revision for important intellectual content MN: Acquisition of data, critical revision for important intellectual content CI: Acquisition of data, critical revision of the manuscript for important intellectual content ALL: Study concept and design, analysis and interpretation of data, drafting of the manuscript, critical revision for important intellectual content All authors have read and approved the manuscript.

Funding
Support for Ariel Bar-Mashiah was provided by the Digestive Diseases Research Fund. He was involved in data acquisition, analysis and interpretation of data, drafting of the manuscript, critical revision for important intellectual content and statistical analysis. Dr. Lucas receives support from the American Cancer Society 129387-MRSG-16-015-01-CPHPS and was involved in study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision for important intellectual content. Dr. Lucas is the principal investigator of the study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All research pertaining to this study was approved by the Mount Sinai Institutional Review Board. Informed consent was obtained from all patients in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 13 October 2019 Accepted: 19 May 2020 Published online: 27 May 2020
References
1. Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
3. Al-Sukhni W, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet. 2008;124(3):271–8.
4. Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the international Cancer of the pancreas screening (CAPS) consortium. Gastroenterology. 2009;136(1):1–17.
5. Jones S, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217.
6. Kastrinos F, et al. Risk of pancreatic cancer in families with lynch syndrome. JAMA. 2009;302(16):1790–5.
7. Rebourc V, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103(1):111–9.
8. Roberts NJ, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6.
9. van Lier MGF, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258–64 author reply 1265.
10. Zhen DB, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PAGCNE study. Genet Med. 2015;17(7):569–77.
11. Canto MI, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology. 2018;155(3):740–51 e2.
12. Canto MI, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804 quiz e14–5.
13. Abe T, et al. Deleterious Germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol. 2019;37(13):1070–80.
14. Pannala R, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88–95.
15. Pannala R, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):S81–7.
16. Sharma A, et al. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490–500 e2.
17. Canto MI, et al. International Cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.
18. Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62 quiz 263.
19. Tanaka M, et al. Revisions of international consensus fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(3):378–53.
20. Tada M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol. 2006;4(10):1265–70.
21. Pani LN, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham offspring study and the National Health and nutrition examination survey 2001-2004. Diabetes Care. 2008;31(10):1991–6.
22. Bosetti C, et al. Cigarette smoking and pancreatic cancer: an analysis from the International pancreatic cancer case-control consortium (Panc4). Ann Oncol. 2012;23(7):1880–8.
23. Paiella S, et al. Results of first-round of surveillance in individuals at high-risk of pancreatic Cancer from the AISP (Italian Association for the Study of the pancreas) registry. Am J Gastroenterol. 2019;114(6):665–70.
24. Hart PA, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016;1(3):26–8.
25. Charl ST, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129(2):504–11.
26. Garg SK, et al. Glycemic Profile of Subjects with Familial Pancreatic Cancer: Mayo Clinic Experience from 2000-2018. Gastroenterology. 2019;156(5):33–8.
27. Boursi B, et al. A clinical prediction model to assess risk for pancreatic Cancer among patients with new-onset diabetes. Gastroenterology. 2017;152(4):840–50 e3.
28. Hart PA, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011;40(3):768–72.
29. Arslan AA, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic Cancer cohort consortium (PanScan). Arch Intern Med. 2010;170(9):791–802.
30. Genkinger JM, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129(7):1708–17.
31. Jao L, et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control. 2010;21(8):1305–14.
32. Amin S, Boffetta P, Lucas AL. The role of common pharmaceutical agents on the prevention and treatment of pancreatic Cancer. Gut Liver. 2016;10(5):665–71.
33. Amin S, et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. Am J Gastroenterol. 2016;111(9):1350–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.